Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Deciphera Pharmaceuticals Inc | DCPH | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 25.51 | 03:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 25.51 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 9.90 - 25.55 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 25.51 | USD |
Deciphera Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.06B | 80.80M | - | 163.36M | -194.94M | -2.41 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Deciphera Pharmaceuticals News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DCPH Price Data
| Period †| Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 25.53 | 25.54 | 25.47 | 25.50 | 1,054,071 | -0.02 | -0.08% |
| 1 Month | 25.29 | 25.55 | 25.27 | 25.41 | 1,817,804 | 0.22 | 0.87% |
| 3 Months | 16.92 | 25.55 | 14.00 | 23.65 | 1,869,881 | 8.59 | 50.77% |
| 6 Months | 12.28 | 25.55 | 12.28 | 21.45 | 1,179,144 | 13.23 | 107.74% |
| 1 Year | 13.78 | 25.55 | 9.90 | 18.70 | 860,637 | 11.73 | 85.12% |
| 3 Years | 33.80 | 38.91 | 6.51 | 15.20 | 953,873 | -8.29 | -24.53% |
| 5 Years | 23.21 | 71.11 | 6.51 | 23.47 | 765,120 | 2.30 | 9.91% |
Deciphera Pharmaceuticals Description
| Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States. |
